Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2003
05/15/2003CA2464529A1 Method of treating estrogen responsive breast cancer
05/15/2003CA2464528A1 Pharmaceutical composition
05/15/2003CA2464007A1 Methods for treating ocular neovascular diseases
05/15/2003CA2462502A1 Improved use of antitumoral compound in cancer therapy
05/15/2003CA2462158A1 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
05/15/2003CA2461373A1 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
05/15/2003CA2461183A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
05/15/2003CA2459745A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
05/14/2003EP1310797A2 Method of monitoring neuroprotective treatment
05/14/2003EP1310552A2 Posh nucleic acids, polypeptides and related methods
05/14/2003EP1310514A2 A silane copolymer and process for preparing the same
05/14/2003EP1310257A2 Hormonal contraceptive combination
05/14/2003EP1310244A2 Compositions comprising an anticancer agent and a polyether block copolymer
05/14/2003EP1309721A2 Modulating multiple lineage kinase proteins
05/14/2003EP1309704A2 Regulation of human membrane-type serine protease
05/14/2003EP1309703A2 Kallikrein gene
05/14/2003EP1309697A2 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
05/14/2003EP1309693A2 Anti-dual integrin antibodies, compositions, methods and uses
05/14/2003EP1309692A2 Anti-il-12 antibodies, compositions, methods and uses
05/14/2003EP1309691A2 Anti-tnf antibodies, compositions, methods and uses
05/14/2003EP1309687A2 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
05/14/2003EP1309685A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
05/14/2003EP1309627A1 Immunotherapy for chronic myelocytic leukemia
05/14/2003EP1309626A2 Cng2b: a putative human cyclic nucleotide-gated ion channel
05/14/2003EP1309622A2 Lat peptides and their use in assays for identifying immunosuppressants
05/14/2003EP1309609A2 Lactam compounds and their use as inhibitors of serine proteases and method
05/14/2003EP1309590A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents
05/14/2003EP1309544A1 Compounds acting as melanocortin receptor ligands
05/14/2003EP1309503A1 Spray device
05/14/2003EP1309374A2 Methods and compositions for treating ige-related disease using nnt-1 inhibitors
05/14/2003EP1309350A2 Chelerythrine-based therapies for cancer
05/14/2003EP1309349A2 Pharmaceutical composition and method for the treatment of retroviral infections
05/14/2003EP1309346A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
05/14/2003EP1309341A2 Prevention and treatment of alzheimer's disease
05/14/2003EP1309339A2 Stimulating neutrophil function to treat inflammatory bowel disease
05/14/2003EP1309337A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage
05/14/2003EP1309334A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
05/14/2003EP1309331A2 Medicine for fighting against sexual dysfunction
05/14/2003EP1309329A2 Therapeutic combination of a cetp inhibitor and atorvastatin
05/14/2003EP1309328A1 Cox-2 inhibitors and the prevention of the side effects of radiation therapy
05/14/2003EP1309325A1 Anticonvulsant derivatives useful for the treatment of depression
05/14/2003EP1309316A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
05/14/2003EP1309315A2 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
05/14/2003EP1309314A2 Method of making tablets and tablet compositions produced therefrom
05/14/2003EP1267940B1 Compounds for targeting
05/14/2003EP1246631B1 Method and device for increasing and/or decreasing the concentration of immunomodulatory-active substances in substance mixtures
05/14/2003EP1140888B1 Optical molecular sensors for cytochrome p450 activity
05/14/2003EP1140189B1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
05/14/2003EP0979096B1 Treatment of infarcts through inhibition of nf-kappab
05/14/2003EP0799314B1 PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES
05/14/2003EP0797427B1 Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
05/14/2003CN1418185A Aniline-derived ligands for thyroid receptor
05/14/2003CN1418121A Compound with 5-HT1A activity useful for treating disorders of outer retina
05/14/2003CN1418113A medicinal aerosol formulation
05/14/2003CN1418109A Drugs for complications of diabetes and neuropathy and utilization thereof
05/14/2003CN1418106A 疫苗 Vaccine
05/14/2003CN1418100A Compounds with 5-HT activity useful for controlling visual field loss
05/14/2003CN1418098A Tamper-resistant oral opioid agonist formulations
05/14/2003CN1418095A Ocular growth and nicotinic antagonists
05/14/2003CN1418091A Pharmaceutical preparations
05/14/2003CN1418089A Pharmaceutical composition of glycogen phosphorylase inhibitors
05/14/2003CN1418087A Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light
05/14/2003CN1417326A Latent-energy regeneration cell
05/14/2003CN1416901A Compound oral prepn for treating pyloric spirobacterium infection
05/14/2003CN1416898A Prepn process of specific fusion vaccine
05/14/2003CN1416897A Prepn process of expression library fusion vaccine
05/14/2003CN1416812A Liver-targeting mitomycin magnetic nano particle and its prepn and application in medicine
05/13/2003US6564152 Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists
05/13/2003US6562978 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS
05/13/2003US6562872 Emulsion of perfluoroorganic compounds for medical purposes, a process for the preparation thereof and methods for treating and preventing diseases with the use thereof
05/13/2003US6562865 Composition comprising a tramadol material and an anticonvulsant drug
05/13/2003US6562864 Catechin multimers as therapeutic drug delivery agents
05/13/2003US6562860 Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
05/13/2003US6562855 Comprises a formulation. The formulation comprises an NMDA antagonist and an alpha-2 adrenergic agonist. In a preferred aspect, there is provided an improved anaesthetic comprising an NMDA antagonist and an alpha-2 adrenergic agonist.
05/13/2003US6562836 Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes
05/13/2003US6562794 Cosmetic and dermatological formulations comprising flavonoids
05/13/2003US6562785 Antimicrobial agent permeabilizes bacterial but not non-bacterial cell and is sufficient to transiently permeabilize the bacteria; toxic agent is only toxic upon entry into the antibiotic resistant bacteria
05/13/2003US6562613 Recombinant C-proteinase and processes, methods and uses thereof
05/13/2003US6562606 Methods and compositions for disrupting the epithelial barrier function
05/13/2003US6562593 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/13/2003US6562582 Removing preferential microorganism from sample; obtain sample, incubate with prophylactic agent, monitor sample for presence of microorganism
05/13/2003US6562381 (+)-Cycloolivil as antioxidant obtained from natural source namely stereospermum personatum
05/13/2003US6562380 Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen
05/13/2003US6562378 Nutritional supplement for adolescents
05/13/2003US6562336 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
05/13/2003US6562335 NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
05/13/2003US6562329 Administering lipase inhibitors
05/13/2003CA2259655C 1,4-di-sustituted piperidines as muscarinic antagonists
05/10/2003WO2002036120A1 Use of stimulators of soluble guanylate cyclase for treating osteoporosis
05/10/2003CA2427551A1 Use of stimulators of soluble guanylate cyclase for treating osteoporosis
05/09/2003CA2464707A1 Compositions for treatment of postmenopausal female sexual dysfunction
05/08/2003WO2003038129A2 Methods for assessing and treating leukemia
05/08/2003WO2003038113A2 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
05/08/2003WO2003038088A1 Molecular diagnosis method for multiple myeloma
05/08/2003WO2003038060A2 Small molecule inhibitors targeted at bcl-2
05/08/2003WO2003038052A2 Nucleic acid-associated proteins
05/08/2003WO2003038043A2 Combinations of dr5 antibody and other therapeutic agents
05/08/2003WO2003038037A2 Glycogen synthase kinase function in endothelial cells
05/08/2003WO2003038030A1 Device with recessed tracks for forming a cellular network
05/08/2003WO2003037913A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
1 ... 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 ... 1151